ARTICLE | Clinical News
Cytran completes IM862 Phase III
February 22, 2001 8:00 AM UTC
Cytran (Kirkland, Wash.) completed enrollment of 200 patients in a Phase III study of its IM862 immune stimulator and angiogenesis inhibitor dipeptide to treat AIDS-related Kaposi's sarcoma. Separatel...